ResearcherAmsterdam University Medical CentersActive in the last 2 years
Thijmen H.T. Broekman
Matched on ORCID iD 0009-0001-1992-4065; OpenAlex author ID A5086348268. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 2, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 31
2023: 1 paper · 2024: none · 2025: none · 2026: 4 papers
Papers 5
- Comparing short- and long-term survivors in metastatic pancreatic cancer: Insights into patient and disease profiles impacting systemic therapy outcomes. Co-author DOI 10.1016/j.ejca.2026.116263↗
- Treatment considerations in patients with metastatic pancreatic cancer who did not receive systemic therapy: A population-based study. Co-author DOI 10.1016/j.ejca.2026.116943↗
- Regional variation for tumour-directed treatment and survival in patients with pancreatic adenocarcinoma: a nationwide population-based analysis. Co-author DOI 10.1016/j.hpb.2025.12.035↗
- Real-world implementation of a decision aid for treatment decisions in metastatic pancreatic cancer: a prospective multicenter study across expert centers. First author DOI 10.1093/oncolo/oyag373↗
- Timing of start of systemic treatment in patients with asymptomatic metastasized pancreatic cancer (TIMEPAN): a protocol of a multicenter prospective patient p… First author DOI 10.1080/0284186x.2023.2273898↗
Closest collaborators
The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Johanna W. Wilmink · 5 shared papers, 2023–2026 · strength 1.09
- Paper Comparing short- and long-term survivors in metastatic pancreatic cancer: Insights into patient and disease profiles im… DOI 10.1016/j.ejca.2026.116263↗
- Paper Treatment considerations in patients with metastatic pancreatic cancer who did not receive systemic therapy: A populati… DOI 10.1016/j.ejca.2026.116943↗
- Paper Regional variation for tumour-directed treatment and survival in patients with pancreatic adenocarcinoma: a nationwide … DOI 10.1016/j.hpb.2025.12.035↗
- Judith de Vos‐Geelen · 5 shared papers, 2023–2026 · strength 1.09
- Paper Comparing short- and long-term survivors in metastatic pancreatic cancer: Insights into patient and disease profiles im… DOI 10.1016/j.ejca.2026.116263↗
- Paper Treatment considerations in patients with metastatic pancreatic cancer who did not receive systemic therapy: A populati… DOI 10.1016/j.ejca.2026.116943↗
- Paper Regional variation for tumour-directed treatment and survival in patients with pancreatic adenocarcinoma: a nationwide … DOI 10.1016/j.hpb.2025.12.035↗
- Marjolein Y.V. Homs · 5 shared papers, 2023–2026 · strength 1.09
- Paper Comparing short- and long-term survivors in metastatic pancreatic cancer: Insights into patient and disease profiles im… DOI 10.1016/j.ejca.2026.116263↗
- Paper Treatment considerations in patients with metastatic pancreatic cancer who did not receive systemic therapy: A populati… DOI 10.1016/j.ejca.2026.116943↗
- Paper Regional variation for tumour-directed treatment and survival in patients with pancreatic adenocarcinoma: a nationwide … DOI 10.1016/j.hpb.2025.12.035↗
- Lydia G. van der Geest · 4 shared papers, 2026 · strength 0.94
- Paper Comparing short- and long-term survivors in metastatic pancreatic cancer: Insights into patient and disease profiles im… DOI 10.1016/j.ejca.2026.116263↗
- Paper Treatment considerations in patients with metastatic pancreatic cancer who did not receive systemic therapy: A populati… DOI 10.1016/j.ejca.2026.116943↗
- Paper Regional variation for tumour-directed treatment and survival in patients with pancreatic adenocarcinoma: a nationwide … DOI 10.1016/j.hpb.2025.12.035↗
- Marc G. Besselink · 4 shared papers, 2023–2026 · strength 0.82
- Paper Treatment considerations in patients with metastatic pancreatic cancer who did not receive systemic therapy: A populati… DOI 10.1016/j.ejca.2026.116943↗
- Paper Regional variation for tumour-directed treatment and survival in patients with pancreatic adenocarcinoma: a nationwide … DOI 10.1016/j.hpb.2025.12.035↗
- Paper Real-world implementation of a decision aid for treatment decisions in metastatic pancreatic cancer: a prospective mult… DOI 10.1093/oncolo/oyag373↗
- Merlijn U.J.E. Graus · 3 shared papers, 2026 · strength 0.70
- Paper Comparing short- and long-term survivors in metastatic pancreatic cancer: Insights into patient and disease profiles im… DOI 10.1016/j.ejca.2026.116263↗
- Paper Treatment considerations in patients with metastatic pancreatic cancer who did not receive systemic therapy: A populati… DOI 10.1016/j.ejca.2026.116943↗
- Paper Real-world implementation of a decision aid for treatment decisions in metastatic pancreatic cancer: a prospective mult… DOI 10.1093/oncolo/oyag373↗
- Jeanin Elise van Hooft · 3 shared papers, 2026 · strength 0.69
- Paper Comparing short- and long-term survivors in metastatic pancreatic cancer: Insights into patient and disease profiles im… DOI 10.1016/j.ejca.2026.116263↗
- Paper Regional variation for tumour-directed treatment and survival in patients with pancreatic adenocarcinoma: a nationwide … DOI 10.1016/j.hpb.2025.12.035↗
- Paper Real-world implementation of a decision aid for treatment decisions in metastatic pancreatic cancer: a prospective mult… DOI 10.1093/oncolo/oyag373↗
- Ignace H. J. T. de Hingh · 3 shared papers, 2026 · strength 0.69
- Paper Comparing short- and long-term survivors in metastatic pancreatic cancer: Insights into patient and disease profiles im… DOI 10.1016/j.ejca.2026.116263↗
- Paper Regional variation for tumour-directed treatment and survival in patients with pancreatic adenocarcinoma: a nationwide … DOI 10.1016/j.hpb.2025.12.035↗
- Paper Real-world implementation of a decision aid for treatment decisions in metastatic pancreatic cancer: a prospective mult… DOI 10.1093/oncolo/oyag373↗
- Hjalmar C. van Santvoort · 2 shared papers, 2026 · strength 0.42
- Paper Regional variation for tumour-directed treatment and survival in patients with pancreatic adenocarcinoma: a nationwide … DOI 10.1016/j.hpb.2025.12.035↗
- Paper Real-world implementation of a decision aid for treatment decisions in metastatic pancreatic cancer: a prospective mult… DOI 10.1093/oncolo/oyag373↗
- Simone Augustinus · 2 shared papers, 2023–2026 · strength 0.39
- Paper Regional variation for tumour-directed treatment and survival in patients with pancreatic adenocarcinoma: a nationwide … DOI 10.1016/j.hpb.2025.12.035↗
- Paper Timing of start of systemic treatment in patients with asymptomatic metastasized pancreatic cancer (TIMEPAN): a protoco… DOI 10.1080/0284186x.2023.2273898↗
- Lois A. Daamen · 2 shared papers, 2023–2026 · strength 0.33
- Paper Real-world implementation of a decision aid for treatment decisions in metastatic pancreatic cancer: a prospective mult… DOI 10.1093/oncolo/oyag373↗
- Paper Timing of start of systemic treatment in patients with asymptomatic metastasized pancreatic cancer (TIMEPAN): a protoco… DOI 10.1080/0284186x.2023.2273898↗
- Hanneke W.M. van Laarhoven · 2 shared papers, 2023–2026 · strength 0.33
- Paper Real-world implementation of a decision aid for treatment decisions in metastatic pancreatic cancer: a prospective mult… DOI 10.1093/oncolo/oyag373↗
- Paper Timing of start of systemic treatment in patients with asymptomatic metastasized pancreatic cancer (TIMEPAN): a protoco… DOI 10.1080/0284186x.2023.2273898↗
- Casper W.F. van Eijck · 1 shared paper, 2026 · strength 0.27
- Aniek E. van Diepen · 1 shared paper, 2026 · strength 0.27
- Tara M. Mackay · 1 shared paper, 2026 · strength 0.25
- Vincent Erwin de Meijer · 1 shared paper, 2026 · strength 0.24
- Marion B.M. van der Kolk · 1 shared paper, 2026 · strength 0.24
- Bert A. Bonsing · 1 shared paper, 2026 · strength 0.24
- N C Biesma · 1 shared paper, 2026 · strength 0.24
- Hanneke W. Wilmink · 1 shared paper, 2026 · strength 0.18
- Izaak Quintus Molenaar · 1 shared paper, 2026 · strength 0.18
- Inez M. Verpalen · 1 shared paper, 2026 · strength 0.18
- Bas Groot Koerkamp · 1 shared paper, 2026 · strength 0.18
- Brigitte C.M. Haberkorn · 1 shared paper, 2026 · strength 0.18
- Marco J. Bruno · 1 shared paper, 2026 · strength 0.18
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.